AKEBIA THERAPEUTICS INC (AKBA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:AKBA • US00972D1054

1.38 USD
+0.01 (+0.73%)
At close: Feb 5, 2026
1.38 USD
0 (0%)
After Hours: 2/5/2026, 4:10:57 PM
Fundamental Rating

4

AKBA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. There are concerns on the financial health of AKBA while its profitability can be described as average. AKBA is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • AKBA had negative earnings in the past year.
  • AKBA had a positive operating cash flow in the past year.
  • AKBA had negative earnings in each of the past 5 years.
  • In the past 5 years AKBA always reported negative operating cash flow.
AKBA Yearly Net Income VS EBIT VS OCF VS FCFAKBA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • AKBA has a Return On Assets of -4.37%. This is amongst the best in the industry. AKBA outperforms 86.45% of its industry peers.
  • AKBA has a Return On Equity of -38.24%. This is in the better half of the industry: AKBA outperforms 71.95% of its industry peers.
  • The Return On Invested Capital of AKBA (6.90%) is better than 93.51% of its industry peers.
Industry RankSector Rank
ROA -4.37%
ROE -38.24%
ROIC 6.9%
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKBA Yearly ROA, ROE, ROICAKBA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • The Operating Margin of AKBA (8.95%) is better than 91.03% of its industry peers.
  • Looking at the Gross Margin, with a value of 82.52%, AKBA belongs to the top of the industry, outperforming 86.07% of the companies in the same industry.
  • AKBA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 8.95%
PM (TTM) N/A
GM 82.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
AKBA Yearly Profit, Operating, Gross MarginsAKBA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • AKBA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • AKBA has more shares outstanding than it did 1 year ago.
  • AKBA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, AKBA has a worse debt to assets ratio.
AKBA Yearly Shares OutstandingAKBA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
AKBA Yearly Total Debt VS Total AssetsAKBA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -4.54, we must say that AKBA is in the distress zone and has some risk of bankruptcy.
  • AKBA has a Altman-Z score of -4.54. This is comparable to the rest of the industry: AKBA outperforms 40.84% of its industry peers.
  • AKBA has a debt to FCF ratio of 5.97. This is a neutral value as AKBA would need 5.97 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 5.97, AKBA belongs to the best of the industry, outperforming 91.60% of the companies in the same industry.
  • AKBA has a Debt/Equity ratio of 4.30. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 4.30, AKBA is doing worse than 80.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 4.3
Debt/FCF 5.97
Altman-Z -4.54
ROIC/WACC0.87
WACC7.96%
AKBA Yearly LT Debt VS Equity VS FCFAKBA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.94 indicates that AKBA should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.94, AKBA is doing worse than 75.95% of the companies in the same industry.
  • A Quick Ratio of 1.80 indicates that AKBA should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.80, AKBA is doing worse than 75.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.8
AKBA Yearly Current Assets VS Current LiabilitesAKBA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • AKBA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.57%, which is quite impressive.
  • AKBA shows a strong growth in Revenue. In the last year, the Revenue has grown by 32.49%.
  • AKBA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -13.72% yearly.
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)32.49%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.01%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.23% on average over the next years. This is a very strong growth
  • AKBA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.72% yearly.
EPS Next Y113.6%
EPS Next 2Y53.22%
EPS Next 3Y36.92%
EPS Next 5Y26.23%
Revenue Next Year58.44%
Revenue Next 2Y39.29%
Revenue Next 3Y28.81%
Revenue Next 5Y23.72%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AKBA Yearly Revenue VS EstimatesAKBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
AKBA Yearly EPS VS EstimatesAKBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AKBA. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 12.03, AKBA is valued correctly.
  • 98.09% of the companies in the same industry are more expensive than AKBA, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 27.50. AKBA is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 12.03
AKBA Price Earnings VS Forward Price EarningsAKBA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AKBA is valued cheaply inside the industry as 95.80% of the companies are valued more expensively.
  • AKBA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AKBA is cheaper than 98.28% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.38
EV/EBITDA 12.78
AKBA Per share dataAKBA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AKBA's earnings are expected to grow with 36.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.22%
EPS Next 3Y36.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AKBA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AKEBIA THERAPEUTICS INC

NASDAQ:AKBA (2/5/2026, 4:10:57 PM)

After market: 1.38 0 (0%)

1.38

+0.01 (+0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-11
Inst Owners47.63%
Inst Owner Change-6.11%
Ins Owners3.57%
Ins Owner Change0%
Market Cap366.21M
Revenue(TTM)225.07M
Net Income(TTM)-15.90M
Analysts87.27
Price Target5.51 (299.28%)
Short Float %14.8%
Short Ratio12.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)100%
Min EPS beat(2)100%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)85.7%
Min EPS beat(4)-22.55%
Max EPS beat(4)165.36%
EPS beat(8)5
Avg EPS beat(8)49.92%
EPS beat(12)8
Avg EPS beat(12)29.94%
EPS beat(16)9
Avg EPS beat(16)25.61%
Revenue beat(2)1
Avg Revenue beat(2)14.3%
Min Revenue beat(2)-1.07%
Max Revenue beat(2)29.66%
Revenue beat(4)3
Avg Revenue beat(4)18.97%
Min Revenue beat(4)-1.07%
Max Revenue beat(4)29.66%
Revenue beat(8)3
Avg Revenue beat(8)1.71%
Revenue beat(12)4
Avg Revenue beat(12)-0.75%
Revenue beat(16)8
Avg Revenue beat(16)11.83%
PT rev (1m)0%
PT rev (3m)-27.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)46.43%
EPS NY rev (1m)0%
EPS NY rev (3m)300%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 12.03
P/S 1.63
P/FCF 11.38
P/OCF 11.3
P/B 8.8
P/tB N/A
EV/EBITDA 12.78
EPS(TTM)-0.07
EYN/A
EPS(NY)0.11
Fwd EY8.32%
FCF(TTM)0.12
FCFY8.79%
OCF(TTM)0.12
OCFY8.85%
SpS0.85
BVpS0.16
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.37%
ROE -38.24%
ROCE 8.73%
ROIC 6.9%
ROICexc 24.74%
ROICexgc 301.13%
OM 8.95%
PM (TTM) N/A
GM 82.52%
FCFM 14.3%
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 4.3
Debt/FCF 5.97
Debt/EBITDA 5.88
Cap/Depr 2.17%
Cap/Sales 0.1%
Interest Coverage 250
Cash Conversion 106.44%
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.8
Altman-Z -4.54
F-Score4
WACC7.96%
ROIC/WACC0.87
Cap/Depr(3y)0.13%
Cap/Depr(5y)0.3%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y113.6%
EPS Next 2Y53.22%
EPS Next 3Y36.92%
EPS Next 5Y26.23%
Revenue 1Y (TTM)32.49%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.01%
Revenue Next Year58.44%
Revenue Next 2Y39.29%
Revenue Next 3Y28.81%
Revenue Next 5Y23.72%
EBIT growth 1Y162.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y142.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y142.77%
OCF growth 3YN/A
OCF growth 5YN/A

AKEBIA THERAPEUTICS INC / AKBA FAQ

What is the fundamental rating for AKBA stock?

ChartMill assigns a fundamental rating of 4 / 10 to AKBA.


What is the valuation status for AKBA stock?

ChartMill assigns a valuation rating of 6 / 10 to AKEBIA THERAPEUTICS INC (AKBA). This can be considered as Fairly Valued.


How profitable is AKEBIA THERAPEUTICS INC (AKBA) stock?

AKEBIA THERAPEUTICS INC (AKBA) has a profitability rating of 4 / 10.


What is the financial health of AKEBIA THERAPEUTICS INC (AKBA) stock?

The financial health rating of AKEBIA THERAPEUTICS INC (AKBA) is 3 / 10.